Japanese drug-maker Shionogi's COVID-19 pill Xocova, also known as S-217622, is seen in this handout picture delivered to Reuters on July 20, 2022.Japanese drug-maker Shionogi's COVID-19 pill Xocova, also known as S-217622, is seen in this handout picture delivered to Reuters on July 20, 2022.
Health experts on the panel voted on Wednesday to await more data from ongoing clinical trials and continue discussions on the drug, dealing another blow to Shionogi’s global ambitions for the antiviral pill. The company has signed an agreement to sell about a million doses to the Japanese government, pending the drug’s approval.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: